Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 14/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 8/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30910928 | 0.89 | BRD4 (0.46) | BRD4S1PR3S1PR4S1PR2S1PR1 | |
| SCHEMBL21831379 | 0.89 | BRD4 (0.46) | BRD4S1PR3S1PR4S1PR2S1PR1 | |
| SCHEMBL21910243 | 0.83 | BRD4 (0.51) | BRD4S1PR3S1PR4S1PR2S1PR1 | |
| SCHEMBL21831494 | 0.83 | LMNA (0.44) | BRD4S1PR3S1PR4S1PR2S1PR1 | |
| SCHEMBL31283048 | 0.82 | ALDH1A1 (0.46) | BRD4S1PR3S1PR4S1PR2L3MBTL1 | |
| SCHEMBL132881 | 0.82 | ALDH1A1 (0.46) | BRD4S1PR3S1PR4S1PR2L3MBTL1 | |
| SCHEMBL5657348 | 0.79 | NOS3 (0.42) | BRD4S1PR3S1PR4S1PR2S1PR1 | |
| SCHEMBL23882704 | 0.79 | S1PR3 (0.54) | S1PR3S1PR4S1PR2S1PR1 | |
| SCHEMBL5133507 | 0.77 | LTA4H (0.37) | BRD4S1PR3S1PR4S1PR2S1PR1 | |
| SCHEMBL20804108 | 0.77 | MAOA (0.48) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262185-B2 | Benzazepine derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1422228-A1 | BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | CYP1B1, CYP1A1, CYP2E1 | BRD4 156/4885S1PR3 1042/4885S1PR4 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.